Page last updated: 2024-11-07

pk 9084

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

PK 9084: anticonflict & anticonvulsant quinoline derivative; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID156894
SCHEMBL ID11174073
MeSH IDM0095479

Synonyms (8)

Synonym
pk 9084
pk-9084
77472-99-2
quinoline, 2-phenyl-4-(2-(3-piperidinyl)ethyl)-
SCHEMBL11174073
2-phenyl-4-(2-(piperidin-3-yl)ethyl)quinoline
2-phenyl-4-[2-(piperidin-3-yl)ethyl]quinoline
DTXSID00998670

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" 3 When the phenylquinolines were combined with chlordiazepoxide the degree of sedation was equal to that seen with either drug given alone, whichever produced the greater sedation; the sedative effects of the two drugs were never additive."( Sedative effects of PK 9084 and PK 8165, alone and in combination with chlordiazepoxide.
File, SE, 1983
)
0.59
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-199015 (88.24)18.7374
1990's2 (11.76)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.39

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.39 (24.57)
Research Supply Index2.89 (2.92)
Research Growth Index4.28 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.39)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]